tag:blogger.com,1999:blog-2029854101173920273.post5298090105819748940..comments2024-01-23T19:29:37.589+00:00Comments on In sickness and in health: Cardiologists circumspect on stellar JUPITER resultsHelen Jaqueshttp://www.blogger.com/profile/00100245108392252512noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-2029854101173920273.post-50378888106424292942008-11-25T14:11:00.000+00:002008-11-25T14:11:00.000+00:00The PLoS Medicine blog has an interesting post abo...The PLoS Medicine blog has <A HREF="http://www.plos.org/cms/node/423" REL="nofollow">an interesting post</A> about the NEJM online poll on whether doctors will change their practice on the basis of the results of the JUPITER trial.Helen Jaqueshttps://www.blogger.com/profile/00100245108392252512noreply@blogger.comtag:blogger.com,1999:blog-2029854101173920273.post-68841508018245363032008-11-14T21:31:00.000+00:002008-11-14T21:31:00.000+00:00Yeah, one of the issues with this study is that it...Yeah, one of the issues with this study is that it wasn't designed to test the clinical utility of measuring CRP levels. As the <A HREF="http://content.nejm.org/cgi/content/full/NEJMe0808320" REL="nofollow">NEJM editorial</A> points out: "the study provides only limited and indirect information about the role of high-sensitivity C-reactive protein testing in clinical management, since the trial did not compare subjects with and those without high-sensitivity C-reactive protein measurements".<BR/><BR/>And you're right, it is pretty important that the makers of rosuvastatin sponsored a trial that had such positive results...Helen Jaqueshttps://www.blogger.com/profile/00100245108392252512noreply@blogger.comtag:blogger.com,1999:blog-2029854101173920273.post-15344251279047157002008-11-13T18:10:00.000+00:002008-11-13T18:10:00.000+00:00It does not make sense to start prescribing statin...It does not make sense to start prescribing statins to people with higher levels of C-reactive proteins simply because it has not been shown that something simpler and cheaper -- taking low-dose aspirin, for instance -- would help reduce generalized inflammation and therefore impact levels of C-reactive protein. <BR/><BR/>And even so, it has not been showed that levels of C-reactive proteins are good predictors of cardiovascular disease, although the study suggests so. <BR/><BR/>Adding to that, there's the fact that the study was commissioned to basically support the use of statins in otherwise healthy people, which would surely benefit AstraZeneca greatly.<BR/><BR/>So I am not surprised that people are cautious. I am, however, surprised by the fact that 47% of those 1,500 physicians are thinking that what they are doing should be changed right now....giohttps://www.blogger.com/profile/01017047918035899600noreply@blogger.com